Literature DB >> 25210149

Lipid phosphate phosphatase-1 expression in cancer cells attenuates tumor growth and metastasis in mice.

Xiaoyun Tang1, Matthew G K Benesch1, Jay Dewald1, Yuan Y Zhao2, Neeraj Patwardhan3, Webster L Santos3, Jonathan M Curtis2, Todd P W McMullen4, David N Brindley1.   

Abstract

Lipid phosphate phosphatase-1 (LPP1) degrades lysophosphatidate (LPA) and attenuates receptor-mediated signaling. LPP1 expression is low in many cancer cells and tumors compared with normal tissues. It was hypothesized from studies with cultured cells that increasing LPP1 activity would decrease tumor growth and metastasis. This hypothesis has never been tested in vivo. To do this, we inducibly expressed LPP1 or a catalytically inactive mutant in cancer cells. Expressing active LPP1 increased extracellular LPA degradation by 5-fold. It also decreased the stimulation of Ca(2+) transients by LPA, a nondephosphorylatable LPA1/2 receptor agonist and a protease-activated receptor-1 peptide. The latter results demonstrate that LPP1 has effects downstream of receptor activation. Decreased Ca(2+) mobilization and Rho activation contributed to the effects of LPP1 in attenuating the LPA-induced migration of MDA-MB-231 breast cancer cells and their growth in 3D culture. Increasing LPP1 expression in breast and thyroid cancer cells decreased tumor growth and the metastasis by up to 80% compared with expression of inactive LPP1 or green fluorescent protein in syngeneic and xenograft mouse models. The present work demonstrates for the first time that increasing the LPP1 activity in three lines of aggressive cancer cells decreases their abilities to produce tumors and metastases in mice.
Copyright © 2014 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  G-protein-coupled receptors; autotaxin; breast cancer; cell migration; epidermal growth factor receptor; lysophosphatidate; thyroid cancer

Mesh:

Substances:

Year:  2014        PMID: 25210149      PMCID: PMC4617140          DOI: 10.1194/jlr.M053462

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  37 in total

1.  Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines.

Authors:  Nicole Euer; Marina Schwirzke; Vesna Evtimova; Helmut Burtscher; Michael Jarsch; David Tarin; Ulrich H Weidle
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

2.  Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fibroblast migration by controlling phospholipase D2-dependent phosphatidate generation.

Authors:  Carlos Pilquil; Jay Dewald; Anton Cherney; Irina Gorshkova; Gabor Tigyi; Denis English; Viswanathan Natarajan; David N Brindley
Journal:  J Biol Chem       Date:  2006-10-21       Impact factor: 5.157

3.  Lipid phosphate phosphohydrolase-1 degrades exogenous glycerolipid and sphingolipid phosphate esters.

Authors:  R Jasinska; Q X Zhang; C Pilquil; I Singh; J Xu; J Dewald; D A Dillon; L G Berthiaume; G M Carman; D W Waggoner; D N Brindley
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

4.  Decreased activities of phosphatidate phosphohydrolase and phospholipase D in ras and tyrosine kinase (fps) transformed fibroblasts.

Authors:  A Martin; A Gomez-Muñoz; D W Waggoner; J C Stone; D N Brindley
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

Review 5.  Integral membrane lipid phosphatases/phosphotransferases: common structure and diverse functions.

Authors:  Yury J Sigal; Mark I McDermott; Andrew J Morris
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

6.  The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases.

Authors:  Ahmed Boucharaba; Claire-Marie Serre; Julien Guglielmi; Jean-Claude Bordet; Philippe Clézardin; Olivier Peyruchaud
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-12       Impact factor: 11.205

7.  Mice with transgenic overexpression of lipid phosphate phosphatase-1 display multiple organotypic deficits without alteration in circulating lysophosphatidate level.

Authors:  Junming Yue; Kazuaki Yokoyama; Louisa Balazs; Daniel L Baker; David Smalley; Carlos Pilquil; David N Brindley; Gabor Tigyi
Journal:  Cell Signal       Date:  2004-03       Impact factor: 4.315

8.  Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes.

Authors:  Abdelkarim Sabri; Jacob Short; Jianfen Guo; Susan F Steinberg
Journal:  Circ Res       Date:  2002-09-20       Impact factor: 17.367

Review 9.  Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer.

Authors:  David N Brindley
Journal:  J Cell Biochem       Date:  2004-08-01       Impact factor: 4.429

10.  The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury.

Authors:  Wenlin Deng; E Shuyu; Ryoko Tsukahara; William J Valentine; Gangadhar Durgam; Veeresa Gududuru; Louisa Balazs; Venkatraman Manickam; Marcello Arsura; Lester VanMiddlesworth; Leonard R Johnson; Abby L Parrill; Duane D Miller; Gabor Tigyi
Journal:  Gastroenterology       Date:  2007-03-24       Impact factor: 22.682

View more
  21 in total

Review 1.  Lipid phosphate phosphatases and their roles in mammalian physiology and pathology.

Authors:  Xiaoyun Tang; Matthew G K Benesch; David N Brindley
Journal:  J Lipid Res       Date:  2015-03-26       Impact factor: 5.922

2.  Lipid phosphate phosphatases: more than one way to put the brakes on LPA signaling?

Authors:  Andrew J Morris; Susan S Smyth
Journal:  J Lipid Res       Date:  2014-09-30       Impact factor: 5.922

3.  Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate.

Authors:  Matthew G K Benesch; Yuan Y Zhao; Jonathan M Curtis; Todd P W McMullen; David N Brindley
Journal:  J Lipid Res       Date:  2015-04-20       Impact factor: 5.922

4.  Tetracyclines increase lipid phosphate phosphatase expression on plasma membranes and turnover of plasma lysophosphatidate.

Authors:  Xiaoyun Tang; Yuan Y Zhao; Jay Dewald; Jonathan M Curtis; David N Brindley
Journal:  J Lipid Res       Date:  2016-02-16       Impact factor: 5.922

Review 5.  Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo.

Authors:  Matthew G K Benesch; Xiaoyun Tang; Ganesh Venkatraman; Raie T Bekele; David N Brindley
Journal:  J Biomed Res       Date:  2015-08-28

6.  Doxycycline attenuates breast cancer related inflammation by decreasing plasma lysophosphatidate concentrations and inhibiting NF-κB activation.

Authors:  Xiaoyun Tang; Xianyan Wang; Yuan Y Zhao; Jonathan M Curtis; David N Brindley
Journal:  Mol Cancer       Date:  2017-02-08       Impact factor: 27.401

7.  Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition.

Authors:  Esther Ekpe-Adewuyi; Ana Lopez-Campistrous; Xiaoyun Tang; David N Brindley; Todd P W McMullen
Journal:  Oncotarget       Date:  2016-12-13

8.  Genome-wide screen identifies a novel prognostic signature for breast cancer survival.

Authors:  Xuan Y Mao; Matthew J Lee; Jeffrey Zhu; Carissa Zhu; Sindy M Law; Antoine M Snijders
Journal:  Oncotarget       Date:  2017-02-21

Review 9.  Emerging role of sphingosine-1-phosphate signaling in head and neck squamous cell carcinoma.

Authors:  Rajeev Nema; Supriya Vishwakarma; Rahul Agarwal; Rajendra Kumar Panday; Ashok Kumar
Journal:  Onco Targets Ther       Date:  2016-05-31       Impact factor: 4.147

Review 10.  Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation.

Authors:  Matthew G K Benesch; Iain T K MacIntyre; Todd P W McMullen; David N Brindley
Journal:  Cancers (Basel)       Date:  2018-03-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.